Pfizer China and Chinaccelerator Launch '2021 Vaccines Open Innovation Challenge'

To better enhance public awareness of disease prevention and vaccination, and to improve the accessibility of medical services, Pfizer China and Chinaccelerator jointly signed a strategic cooperation memorandum in Shanghai on April 15, officially launching the call for entries for the “2021 Vaccine Open Innovation Challenge.”

Both parties will actively join hands to leverage digital innovation and other means to better help people at all stages of life prevent diseases, thereby contributing to the realization of "Healthy China 2030."

Pierre Gaudreault, President of Pfizer Biopharmaceuticals Group China; Wang Yiqin, Vice President of Marketing for Pfizer Biopharmaceuticals Group China; Wei Xin, Head of Business Partnerships for Pfizer’s Digital Team in China; Che Yan, Head of Vaccine Marketing for Pfizer Biopharmaceuticals Group China; Bao Hua, Head of Market Expansion and the Business Innovation Center for Pfizer Biopharmaceuticals Group China; Xu Bin, Director of the Pfizer China and Asia-Pacific Digital Innovation Lab; along with Oscar Ramos, Managing Partner and Managing Director of Chinaccelerator; Huo Meng, Director of Corporate Innovation at Chinaccelerator; and Cai Yiwen, Head of China Partnerships at Chinaccelerator, were among the distinguished guests who attended the signing ceremony.

Wang Yiqin and Oscar Ramos Sign Strategic Cooperation Memorandum of Understanding

Pierre Gaudreault, President of Pfizer’s Biopharmaceuticals Group in China, stated, “At Pfizer, our mission is to ‘deliver breakthroughs that change patients’ lives.’ Breakthrough innovations encompass not only the research and development and introduction of more innovative medicines and vaccines into China, but also close collaboration with partners to jointly accelerate the development of China’s healthcare sector, enabling more people to access better and higher-quality medical services.”

“Through strategic cooperation with VCBeat, we believe we can further enhance public awareness of disease prevention and vaccination, improve the accessibility of medical services, and demonstrate Pfizer’s commitment to ‘delivering breakthroughs that change patients’ lives’ as well as its relentless pursuit of digital innovation.”

"In the future, we will comprehensively advance our strategic partnership in areas such as business strategy, digitalization, and entrepreneurial methodologies. By leveraging our resource advantages in the Chinese market, we aim to deepen exchanges and collaboration with startups, thereby sharing development opportunities, achieving win-win outcomes, and jointly addressing public health challenges, including disease prevention and control."

Prevention is the most cost-effective and efficient health strategy, and vaccines are among the most effective tools for disease prevention. With the mission of “bringing breakthrough innovations that change patients’ lives,” Pfizer consistently advances revolutionary scientific innovation, accelerates the research and development of breakthrough therapies, and delivers innovative medicines and vaccines.

Meanwhile, Pfizer is committed to working with healthcare professionals, governments, communities, and other partners inside and outside the industry around the world to provide innovative solutions that improve patient health outcomes and enhance the service capabilities of healthcare providers, supporting people worldwide in accessing more reliable and affordable healthcare services.

Upholding its global strategy and objectives, Pfizer China has partnered with its strategic partner VCBeat to launch the “2021 Vaccine Open Innovation Challenge,” collaborating with startups worldwide to explore and develop novel, effective digital solutions and harness innovative capabilities.

Pfizer, an innovative biopharmaceutical company dedicated to applying science and its global resources to provide therapies that extend and significantly improve human life. In the exploration, research and development, and manufacturing of healthcare products (including innovative medicines and vaccines), Pfizer has established standards for quality, safety, and value.

Every day, Pfizer employees in developed and emerging markets are dedicated to advancing health, as well as prevention and treatment solutions capable of addressing the most challenging diseases of our time. Pfizer also collaborates with healthcare professionals, governments, and communities around the world to support people everywhere in accessing more reliable and affordable healthcare services. For over 170 years, Pfizer has been committed to providing better and higher-quality services for people.